Active Ingredient History
Lemborexant is a dual orexin receptor antagonist, which inhibits orexin by binding competitively to two subtypes of orexin receptors. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully facilitate the initiation and maintenance of sleep by interfering with orexin neurotransmission with lemborexant. Extensive in vitro and non-clinical testing of lemborexant supported the supposition that lemborexant has a low risk of QT prolongation at therapeutic and supratherapeutic exposures in humans. A Phase III study of lemborexant in insomnia is underway, and in addition, Eisai has announced the initiation of Phase II clinical studies of lemborexant in patients with irregular sleep-wake rhythm disorder. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adult (Phase 2)
Aged (Phase 2)
Alcoholism (Phase 3)
Alzheimer Disease (Phase 2)
Analgesics, Opioid (Phase 1/Phase 2)
Central Nervous System Diseases (Phase 1)
Chronobiology Disorders (Phase 2)
Dementia (Phase 4)
Drug Interactions (Phase 1/Phase 2)
Frontotemporal Dementia (Phase 4)
Healthy Volunteers (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Metabolism (Phase 1)
Pulmonary Disease, Chronic Obstructive (Phase 1)
Respiration Disorders (Phase 1)
Sleep Apnea, Obstructive (Phase 1/Phase 2)
Sleep Disorders, Circadian Rhythm (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
